Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin
AD Ricart - Clinical Cancer Research, 2011 - AACR
Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …
Antibody-drug conjugates for cancer therapy
PJ Carter, PD Senter - The Cancer Journal, 2008 - journals.lww.com
The antibody-drug conjugate (ADC) concept is to use an antibody to deliver a cytotoxic drug
selectively to a target such as a tumor-associated antigen. Such conjugates represent a …
selectively to a target such as a tumor-associated antigen. Such conjugates represent a …
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate
NM Okeley, JB Miyamoto, X Zhang, RJ Sanderson… - Clinical Cancer …, 2010 - AACR
Purpose: SGN-35 is an antibody-drug conjugate (ADC) containing the potent antimitotic
drug, monomethylauristatin E (MMAE), linked to the anti-CD30 monoclonal antibody, cAC10 …
drug, monomethylauristatin E (MMAE), linked to the anti-CD30 monoclonal antibody, cAC10 …
[HTML][HTML] CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
LM Smith, A Nesterova, MC Ryan, S Duniho… - British journal of …, 2008 - nature.com
Abstract CD133/prominin-1 is a pentaspan transmembrane glycoprotein overexpressed in
various solid tumours including colorectal and glioblastomas. CD133 was found here to be …
various solid tumours including colorectal and glioblastomas. CD133 was found here to be …
[HTML][HTML] Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in …
G Maschmeyer, L Bullinger, C Garcia-Vidal… - Leukemia, 2022 - nature.com
The 9th web-based European Conference on Infections in Leukemia (ECIL-9), held
September 16-17, 2021, reviewed the risk of infections and febrile neutropenia associated …
September 16-17, 2021, reviewed the risk of infections and febrile neutropenia associated …
Immunotherapy prospects for acute myeloid leukaemia
AJ Barrett, K Le Blanc - Clinical & Experimental Immunology, 2010 - academic.oup.com
While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML),
the disease has a high probability of relapse. Strategies to prevent relapse involve …
the disease has a high probability of relapse. Strategies to prevent relapse involve …
[HTML][HTML] Gastric cancer stem cells: therapeutic targets
During the past decade, a growing body of evidence has implied that cancer stem cells
(CSCs) play an important role in the development of gastric cancer (GC). The notion that …
(CSCs) play an important role in the development of gastric cancer (GC). The notion that …
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
R Stasi, ML Evangelista, F Buccisano, A Venditti… - Cancer treatment …, 2008 - Elsevier
Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized
anti-CD33 antibody (hP67. 6) linked to N-acetyl-calicheamicin 1, 2-dimethyl hydrazine …
anti-CD33 antibody (hP67. 6) linked to N-acetyl-calicheamicin 1, 2-dimethyl hydrazine …
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
R Stasi - Expert opinion on biological therapy, 2008 - Taylor & Francis
Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …
Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin …
JF DiJoseph, MM Dougher, DY Evans, BB Zhou… - Cancer chemotherapy …, 2011 - Springer
Abstract Purpose CMC-544 (inotuzumab ozogamicin) is a CD22-specific immunoconjugate
of calicheamicin currently being evaluated in patients with non-Hodgkin's B-cell lymphoma …
of calicheamicin currently being evaluated in patients with non-Hodgkin's B-cell lymphoma …